

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
















